These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25123670)

  • 21. Consenting for current genetic research: is Canadian practice adequate?
    Jaitovich Groisman I; Egalite N; Godard B
    BMC Med Ethics; 2014 Nov; 15():80. PubMed ID: 25410958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. When and how to include vulnerable subjects in clinical trials.
    Wendler D
    Clin Trials; 2020 Dec; 17(6):696-702. PubMed ID: 32806931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A review of the most frequent objections made to patient information sheets of clinical trials].
    López-Parra M; Moreno-Quiroga C; Lechuga-Pérez J
    Med Clin (Barc); 2012 Jul; 139(4):176-9. PubMed ID: 22560053
    [No Abstract]   [Full Text] [Related]  

  • 24. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration.
    Bramstedt KA; Kassimatis K
    Clin Invest Med; 2004 Dec; 27(6):316-23. PubMed ID: 15675112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breaking the camel's back: multicenter clinical trials and local institutional review boards.
    Burman WJ; Reves RR; Cohn DL; Schooley RT
    Ann Intern Med; 2001 Jan; 134(2):152-7. PubMed ID: 11177319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The roles, challenges and institutionalization of institutional review boards.
    Oyibo WA; Krugher M; Fagbenro-Beyioku AF
    Nig Q J Hosp Med; 2008; 18(2):115-9. PubMed ID: 19068565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards a balanced approach to identifying conflicts of interest faced by institutional review boards.
    Kaur S; Balan S
    Theor Med Bioeth; 2015 Oct; 36(5):341-61. PubMed ID: 26438122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Institutional review board practices regarding assent in pediatric research.
    Whittle A; Shah S; Wilfond B; Gensler G; Wendler D
    Pediatrics; 2004 Jun; 113(6):1747-52. PubMed ID: 15173501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Institutional review board approval: why it matters.
    Parvizi J; Tarity TD; Conner K; Smith JB
    J Bone Joint Surg Am; 2007 Feb; 89(2):418-26. PubMed ID: 17272462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New federal guidance adds duties for institutional review boards (IRBs).
    Maloney DM
    Hum Res Rep; 2005 Nov; 20(11):1-2. PubMed ID: 16358479
    [No Abstract]   [Full Text] [Related]  

  • 31. Institutional Review Board Considerations for Clinical Trials.
    Mogi M; Liu S
    Methods Mol Biol; 2024; 2766():311-316. PubMed ID: 38270890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Justification and authority in institutional review board decision letters.
    Clapp JT; Gleason KA; Joffe S
    Soc Sci Med; 2017 Dec; 194():25-33. PubMed ID: 29059597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Institutional Review Board Quality, Private Equity, and Promoting Ethical Human Subjects Research.
    Lynch HF; Rosenfeld S
    Ann Intern Med; 2020 Oct; 173(7):558-562. PubMed ID: 32687743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How closely do institutional review boards follow the common rule?
    Lidz CW; Appelbaum PS; Arnold R; Candilis P; Gardner W; Myers S; Simon L
    Acad Med; 2012 Jul; 87(7):969-74. PubMed ID: 22622205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case study: research subject says institutional review board (IRB) would not answer her questions.
    Maloney DM
    Hum Res Rep; 2006 Feb; 21(2):7. PubMed ID: 16789309
    [No Abstract]   [Full Text] [Related]  

  • 36. What Is "Key Information"? Consideration of the Reasons People Do or Do Not Take Part in Research.
    Berwanger K; Merz JF
    Ethics Hum Res; 2024; 46(3):26-33. PubMed ID: 38629224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Institutional review boards (IRBs) and regulations on research with elders.
    Maloney DM
    Hum Res Rep; 2002 Nov; 17(11):9. PubMed ID: 12708415
    [No Abstract]   [Full Text] [Related]  

  • 38. US IRBs confronting research in the developing world.
    Klitzman RL
    Dev World Bioeth; 2012 Aug; 12(2):63-73. PubMed ID: 22515423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials.
    Lantos JD; Wendler D; Septimus E; Wahba S; Madigan R; Bliss G
    Clin Trials; 2015 Oct; 12(5):485-93. PubMed ID: 26374686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paying Research Participants: Regulatory Uncertainty, Conceptual Confusion, and a Path Forward.
    Largent EA; Fernandez Lynch H
    Yale J Health Policy Law Ethics; 2017; 17(1):61-141. PubMed ID: 29249912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.